Welcome to our dedicated page for Revvity news (Ticker: RVTY), a resource for investors and traders seeking the latest updates and insights on Revvity stock.
Revvity, Inc. reports developments for a global life sciences and diagnostics business that provides health science solutions, technologies, expertise and services across workflows from discovery and development to detection and diagnosis. Company updates center on translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and Signals software for pharmaceutical, biotechnology, diagnostic laboratory, academic and government customers.
Recurring announcements include financial results and earnings calls, quarterly dividends, investor conference presentations, governance matters and product introductions. Recent product themes include Signals BioDesign for biologics construct design and research collaboration, Signals One platform integration, high-content imaging, multimode detection, sample preparation, screening and laboratory automation systems.
Revvity (RVTY) launched its CE-IVDR-certified GSP T1D 3plex kit for early type 1 diabetes risk screening on September 24, 2026. The fully automated test detects multiple autoantibodies in capillary dried blood spots processed on Revvity’s GSP instrument, which is also used in newborn screening.
The kit is designed to identify children at risk before symptoms appear. It will initially be available in Europe and markets that accept CE IVD-marked products, but it is not cleared by the U.S. Food and Drug Administration. The offering includes reagents, instrumentation and software, extending Revvity’s diagnostic range into early childhood screening.
Revvity (RVTY) has signed a definitive agreement to acquire France-based Human Cell Design, a specialist in human cell models for metabolic diseases, with closing expected in Q4 2026 subject to customary regulatory approvals.
The deal is expected to add HCD’s EndoC-βH5 human pancreatic beta cell model, specialized media and reagents, preclinical research services, and its NatLine cell-line development platform to Revvity’s Life Sciences portfolio. The combined offering is aimed at supporting drug discovery, screening and preclinical research for diabetes, obesity and next-generation GLP-1 and GPCR-targeting therapies. Integration with Revvity’s HTRF™, AlphaLISA™, pHSense™ and ATPlite™ assays and high-content screening is expected to provide more integrated solutions from early discovery through regenerative medicine and cell therapy quality control.
Revvity (NYSE: RVTY) will present at three upcoming healthcare investor conferences in September 2026. Management participants include CEO Prahlad Singh at the Wells Fargo 21st Annual Healthcare Conference on September 9 at 8:45 a.m. ET, CFO Max Krakowiak at the Morgan Stanley 24th Annual Global Healthcare Conference on September 14 at 8:30 a.m. ET, and SVP Steve Willoughby at Baird’s 2026 Global Healthcare Conference on September 15 at 9:05 a.m. ET.
Attendees will hear updates on the company and its strategic priorities during fireside chats. Live audio webcasts will be accessible via the Events section of Revvity’s website, with replays available on the Investor Relations site for at least 30 days after each event.
Revvity (NYSE:RVTY) reported second quarter 2026 revenue of $730 million versus $720 million a year ago, with pro forma revenue of $711 million, up 4% and 3% pro forma organic growth. GAAP EPS from continuing operations was $0.48 (pro forma $0.52), while adjusted and pro forma adjusted EPS were both $1.41, up from $1.18 and $1.15, respectively, including about $0.11 from tariff-related refunds.
GAAP operating income from continuing operations was $89 million (12.2% margin) versus $91 million (12.6%), while adjusted operating income rose to $211 million (28.9% margin) from $192 million (26.6%). Pro forma adjusted operating income was $209 million, with margin expanding to 29.3% from 26.5%.
Revvity entered a definitive agreement to divest its China Immunodiagnostics business, which represented about 6% of 2025 revenue; closing is expected by end of 2027, subject to customary conditions and regulatory approvals. On a pro forma basis excluding China IDX, 2026 guidance was raised to $2.83–$2.86 billion in revenue, 4–5% pro forma organic growth, and pro forma adjusted EPS of $5.30–$5.40.
Revvity (NYSE: RVTY) announced that its Board of Directors declared a regular quarterly dividend of $0.07 per share of common stock. The dividend will be payable on November 13, 2026 to shareholders of record as of the close of business on October 23, 2026.
Revvity (NYSE: RVTY) released its 2026 Impact Report, detailing sustainability, social and governance activities and performance. The report includes the company’s first disclosure of material Scope 3 greenhouse gas emissions, expanding its sustainability reporting coverage.
Revvity reports a 1.3% reduction in Scope 1 and 2 emissions in 2025, contributing to a 16% total reduction from its 2022 baseline. The company achieved a 49% non-hazardous waste diversion rate, exceeding its 40% annual goal. Talent initiatives reduced voluntary turnover to 7% from 9%, with 24% of open roles filled via internal promotions and transfers. Revvity also launched the Revvity Supports Research initiative, providing $180,000 in general research grants to 12 academic institutions aligned with its supported scientific areas.
Revvity (NYSE:RVTY) will release its second quarter 2026 financial results before market open on Tuesday, August 4, 2026. A conference call to discuss the results will follow at 7:30 a.m. ET, hosted by CEO Prahlad Singh and CFO Max Krakowiak, with a live webcast on the investor website.
Revvity (NYSE:RVTY) expanded its Signals AI ecosystem by integrating with Anthropic’s Model Context Protocol (MCP) directory. The new Signals MCP connector lets scientists use Claude and Claude Science to query Signals’ governed R&D data, organizational knowledge and scientific context via natural language while preserving traceability.
Revvity (NYSE:RVTY) launched Signals AI, a native agentic framework embedded in its Signals One platform to help scientists interact with complex R&D data in natural language. Signals AI uses governed data, scientific ontologies and validated algorithms to generate traceable, context-rich responses and task-ready insights across workflows.
Select capabilities are available now, with more features planned in the coming weeks.
Revvity (NYSE: RVTY) reported Q1 2026 revenue of $711 million and pro forma revenue of $687 million, representing 7% reported growth and 6% pro forma growth versus prior year. GAAP EPS from continuing operations was $0.37; adjusted EPS was $1.06; pro forma adjusted EPS was $1.04.
The company announced intent to divest its China Immunodiagnostics business (≈6% of 2025 revenue), expects a definitive agreement Q2 2026 and completion in 2027 pending approvals. Full-year 2026 pro forma guidance: revenue $2.81–$2.84B, pro forma organic growth 3–4%, pro forma adjusted EPS $5.20–$5.30.